Oncolytics Biotech (ONCY) Current Assets (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Current Assets data on file, last reported at $6.8 million in Q4 2025.

• On a quarterly basis, Current Assets fell 49.35% year-over-year to $6.8 million in Q4 2025; TTM through Dec 2025 was $6.8 million, a 49.35% decrease from a year earlier, with the FY2025 full-year figure at $6.8 million, down 44.97% from the prior year.
• Current Assets for Q4 2025 stood at $6.8 million, down from $10.2 million in the prior quarter.
• Over the last five years, Current Assets for ONCY reached as high as $45.1 million in Q2 2021 and fell as low as $6.8 million in Q4 2025.
• Historically, Current Assets has averaged $25.8 million across 5 years, with a median of $25.8 million in 2022.
• Across the five-year window, Current Assets jumped 37.66% in 2021 and tumbled 51.81% in 2024, its largest moves.
• Year by year, Current Assets stood at $35.6 million in 2021, then retreated by 26.21% to $26.3 million in 2022, then gained by 6.66% to $28.0 million in 2023, then tumbled by 51.81% to $13.5 million in 2024, then tumbled by 49.35% to $6.8 million in 2025.
• Per Business Quant data, the three most recent Current Assets figures were $6.8 million in Q4 2025, $10.2 million in Q3 2025, and $13.6 million in Q2 2025.